Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Arcutis Biotherapeutics (ARQT) over the last 7 years, with Dec 2024 value amounting to -$17.1 million.

  • Arcutis Biotherapeutics' Net Cash Flow fell 150.56% to -$25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.9 million, marking a year-over-year decrease of 425.55%. This contributed to the annual value of -$17.1 million for FY2024, which is 149.67% down from last year.
  • Arcutis Biotherapeutics' Net Cash Flow amounted to -$17.1 million in FY2024, which was down 149.67% from $34.5 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Net Cash Flow ranged from a high of $34.5 million in FY2023 and a low of -$43.1 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$17.1 million (2024), whereas its average is -$8.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 853.98% in 2021, then plummeted by 237.46% in 2022.
  • Arcutis Biotherapeutics' Net Cash Flow (Yearly) stood at $3.3 million in 2020, then surged by 853.98% to $31.4 million in 2021, then slumped by 237.46% to -$43.1 million in 2022, then skyrocketed by 180.01% to $34.5 million in 2023, then tumbled by 149.67% to -$17.1 million in 2024.